
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego.


















